Positive results from ASPEN-1 phase III trial of daxibotulinumtoxina in cervical dystonia meets primary efficacy endpoint at both 125- and 250-Unit doses

Trial (n=301) demonstrated an improvement in signs and symptoms of cervical dystonia at weeks 4 and 6, with statistically significant greater change from baseline vs. placebo on TWSTRS Total Score (12.7 and 10.9 respectively vs. 4.3, p<0.0001 and p=0.0006).

Source:

Biospace Inc.